Department of Immunobiology, Yale University, New Haven, CT 06511, USA.
Trends Mol Med. 2012 Mar;18(3):173-81. doi: 10.1016/j.molmed.2012.01.001. Epub 2012 Feb 17.
Type 1 diabetes is a common autoimmune disease that affects millions of people worldwide and has an incidence that is increasing at a striking rate, especially in young children. It results from the targeted self-destruction of the insulin-secreting β cells of the pancreas and requires lifelong insulin treatment. The effects of chronic hyperglycemia - the result of insulin deficiency - include secondary endorgan complications. Over the past two decades our increased understanding of the pathogenesis of this disease has led to the development of new immunomodulatory treatments. None have yet received regulatory approval, but this report highlights recent progress in this area.
1 型糖尿病是一种常见的自身免疫性疾病，影响着全球数以百万计的人群，其发病率呈惊人的上升趋势，尤其是在儿童中。它是由胰腺分泌胰岛素的β细胞被靶向性自身破坏引起的，需要终身胰岛素治疗。慢性高血糖（胰岛素缺乏的结果）的影响包括次要靶器官并发症。在过去的二十年中，我们对这种疾病发病机制的认识不断加深，导致了新的免疫调节治疗方法的发展。目前尚无一种方法获得监管部门的批准，但本报告强调了该领域的最新进展。
